)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bafna Pharmaceuticals
Bafna Pharmaceuticals (BAFNAPH) investor relations material
Bafna Pharmaceuticals Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary11 Nov, 2026
Executive summary
Board approved unaudited Q2 and H1 results for the period ended September 30, 2026; statutory auditors completed a limited review.
Financial highlights
Q2 revenue from operations was INR 4,766.56 lakh vs INR 3,546.82 lakh YoY; H1 revenue was INR 7,424.88 lakh vs INR 7,009.22 lakh.
Q2 profit for the period was INR 684.82 lakh vs INR 312.49 lakh YoY; H1 profit was INR 692.33 lakh vs INR 651.38 lakh.
H1 total income was INR 7,729.39 lakh vs INR 7,186.75 lakh; total expenses were INR 7,037.06 lakh vs INR 6,535.37 lakh.
Segment performance
Pharmaceutical formulations manufacturing is the sole operating segment under Ind AS 108.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bafna Pharmaceuticals
- Q1 FY27 saw sharp declines in revenue and profit, with GST disputes not impacting outlook.BAFNAPH
Q1 26/27 - FY26 net profit more than doubled year-over-year, with strong revenue growth and clean audit.BAFNAPHQ4 25/26
- Quarterly revenue and profit increased year-over-year, with key tax and GST risks under appeal.BAFNAPHQ3 2026
- Q2 FY26 profit increased to ₹312.49 lakhs, with revenue at ₹3,546.82 lakhs and higher EPS.BAFNAPHQ2 25/26
- Returned to profitability with higher revenue and completed key asset sale in the quarter.BAFNAPHQ1 25/26
- Q2 FY25 saw higher revenue and profit, but compliance and receivable risks persist.BAFNAPHQ2 24/25
- Q1 FY25 posted a net loss and lower revenue, with compliance and receivable risks highlighted.BAFNAPHQ1 24/25
- Net profit fell despite higher revenue, with key assets held for sale and compliance milestones met.BAFNAPHQ4 24/25
- Q3 FY25 marked a return to profitability with higher revenue and no outstanding debt.BAFNAPHQ3 2025
Next Bafna Pharmaceuticals earnings date
Q3 202710 Feb, 2027
Bafna Pharmaceuticals
Next Bafna Pharmaceuticals earnings date
Q3 202710 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bafna Pharmaceuticals Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of generic and branded pharmaceutical formulations. The company produces a range of dosage forms including tablets, capsules, and oral liquids across various therapeutic segments. It supplies its products to both domestic and international markets, with a focus on regulated and semi-regulated regions. Bafna Pharmaceuticals Limited also offers contract manufacturing services and maintains compliance with global quality standards. The company is headquartered in Chennai, India, and its shares are listed on the BSE.